CurrentCommunity-CarePolicy N/A

Intravenous Immune Globulin (IVIG) medical benefit utilization

Defines medical necessity, authorization, quantity limits, and continuation criteria for IVIG (various brands) under the medical benefit for applicable providers and members of the Community-Care plan.

Policy Summary

PayerCommunity-Care

PolicyIntravenous Immune Globulin (IVIG) medical benefit utilization

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateSep 1, 2024

Key ActionObtain prior authorization with diagnosis and specialist prescriber or consultation and provide patient weight when required for approvals.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

24+indications listed

Up to 2 g/kgmax authorized qty

1–12 monthsauthorization durations

J-codes listedHCPCS codes

Coverage Criteria for IVIG

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Covered when ALL of the following are met for each listed indication (indication-specific criteria provided):

Primary immunodeficiency: Diagnosis of a primary immunodeficiency (e.g., agammaglobulinemia due to absence of B cells, hypogammaglobulinemia, normal immunoglobulins with poor antibody function, or a genetically defined primary immunodeficiency) AND prescribed by, or in consultation with, an allergist or immunologist AND one of: inadequate responsiveness to specific antigens (e.g., pneumococcal polysaccharide) OR history of recurrent significant infections.

Hypogammaglobulinemia with CLL or multiple myeloma: Diagnosis of hypogammaglobulinemia with chronic lymphocytic leukemia (CLL) or multiple myeloma AND prescribed by, or in consultation with, an allergist, immunologist, oncologist, or hematologist AND history of recurrent bacterial infections or serious bacterial infections.

HIV-infection (children): Diagnosis of HIV infection in children AND prescribed by, or in consultation with, an infectious disease specialist, allergist, or immunologist AND either: diagnosis of hypogammaglobulinemia requiring primary prophylaxis of bacterial infections OR frequent, recurrent bacterial infections despite antibiotic prophylaxis and combination antiretroviral therapy.

Immune thrombocytopenic purpura (ITP): Diagnosis of ITP AND prescribed by, or in consultation with, a hematologist AND one of: trial of corticosteroids was ineffective, not tolerated, or contraindicated OR platelet level < 30,000/µL AND there is a clinical need to raise platelet levels more rapidly than can be accomplished with corticosteroids.

Dermatomyositis: Diagnosis of dermatomyositis AND prescribed by, or in consultation with, a neurologist or rheumatologist AND disease refractory to at least one prior systemic therapy.

Birdshot retinochoroidopathy: Diagnosis of birdshot retinochoroidopathy AND prescribed by, or in consultation with, a neurologist or rheumatologist AND trial of corticosteroids was ineffective, not tolerated, or contraindicated.

Henoch-Schönlein purpura: Diagnosis of Henoch-Schönlein purpura.

Autoimmune Graves ophthalmopathy: Diagnosis of autoimmune Graves ophthalmopathy.

Guillain-Barré syndrome (GBS): Diagnosis of Guillain-Barré syndrome AND prescribed by, or in consultation with, a neurologist AND treatment initiated within four weeks of onset AND one of: patient is non-ambulatory OR significantly affected and not recovering.

Chronic inflammatory demyelinating polyneuropathy (CIDP): Diagnosis of CIDP AND prescribed by, or in consultation with, a neurologist AND clinical diagnosis confirmed by either diagnosis at a GBS/CIDP Foundation International Center of Excellence OR meeting specified electrodiagnostic criteria (chronically progressive/stepwise/recurrent symmetric proximal and distal weakness and sensory dysfunction for ≥ 2 months; absent or reduced tendon reflexes in all extremities; and electrodiagnostic confirmation per defined thresholds for distal latency, conduction velocity, F-wave latency/absence, partial motor conduction block, or abnormal temporal dispersion).

Multifocal motor neuropathy: Diagnosis of multifocal motor neuropathy AND prescribed by, or in consultation with, a neurologist AND confirmed by slowly progressive focal asymmetric limb weakness >1 month AND absence of the listed sensory, upper motor neuron, bulbar, or diffuse symmetric findings.

Lambert-Eaton myasthenic syndrome: Diagnosis of Lambert-Eaton myasthenic syndrome AND prescribed by, or in consultation with, a neurologist AND diagnosis confirmed by electrodiagnostic studies AND refractory to at least one listed immunosuppressive or glucocorticoid agent.

Acute exacerbation of myasthenia gravis: Prescribed by, or in consultation with, a neurologist AND used for acute exacerbation with difficulty swallowing, acute respiratory failure, or major functional disability.

Refractory myasthenia gravis: Prescribed by, or in consultation with, a neurologist AND diagnosis of refractory myasthenia gravis AND adequate trial (≥ 1 year) of glucocorticoids with azathioprine or mycophenolate was ineffective, contraindicated, or not tolerated AND trial of glucocorticoids with cyclosporine or tacrolimus was ineffective, contraindicated, or not tolerated.

Stiff person syndrome: Diagnosis of stiff person syndrome AND prescribed by, or in consultation with, a neurologist AND trial of a benzodiazepine was ineffective, not tolerated, or contraindicated AND trial of a baclofen product was ineffective, not tolerated, or contraindicated.

Kawasaki disease: Diagnosis of Kawasaki disease AND prescribed by, or in consultation with, an infectious disease specialist AND immune globulin administered within 10 days of symptom onset.

CMV pneumonitis (solid organ transplant): Diagnosis of CMV pneumonitis in a solid organ transplant recipient AND prescribed by, or in consultation with, an infectious disease specialist.

Neonatal sepsis: Diagnosis of neonatal sepsis AND prescribed by, or in consultation with, an infectious disease specialist or neonatologist.

Rotaviral enterocolitis: Diagnosis of rotaviral enterocolitis AND prescribed by, or in consultation with, an infectious disease specialist.

Enteroviral meningoencephalitis: Diagnosis of enteroviral meningoencephalitis AND prescribed by, or in consultation with, an infectious disease specialist or neonatologist.

Toxic epidermal necrolysis: Diagnosis of toxic epidermal necrolysis.

Stevens-Johnson syndrome: Diagnosis of Stevens-Johnson syndrome.

Any other indication: Diagnosis is provided AND documentation of clinical evidence/justification (chart notes, including other agents tried for the condition) for immune globulin use.

Continuation Therapy

Continuation covered when benefit demonstrated:

CIDP continuation: Diagnosis of chronic inflammatory demyelinating polyneuropathy AND demonstrated benefit with the most recent treatment; clinically stable patients with adequate response should be considered for gradual dose reduction to the minimally effective dose.

Multifocal motor neuropathy continuation: Diagnosis of multifocal motor neuropathy AND demonstrated benefit with the most recent treatment.

Lambert-Eaton continuation: Diagnosis of Lambert-Eaton myasthenic syndrome AND demonstrated benefit with the most recent treatment.

Stiff person syndrome continuation: Diagnosis of stiff person syndrome AND demonstrated benefit with the most recent treatment.

There are no blanket exclusions beyond the condition-specific criteria listed in this policy. Use of intravenous immune globulin (IVIG) for diagnoses not explicitly listed requires submission of the diagnosis and supporting clinical evidence/justification (for example, chart notes documenting the condition and prior therapies tried) for review. Requests that do not meet the specified indication criteria or that lack adequate documentation for a non-listed diagnosis will not be supported.

Therapy will not meet coverage criteria when the required diagnostic or consultative documentation is missing. Examples include absence of a documented diagnosis that meets the condition‑specific requirements, lack of a specialist prescriber or documented consultation when one is specified (for example, neurologist, hematologist, infectious disease specialist, immunologist, or neonatologist), or failure to provide clinical justification and prior treatment history for indications categorized as "any other indication." In such situations, prior authorization may be denied.

Billing and Code Information

Applicable HCPCS CodesHCPCS

J1459	Injection, immune globulin (privigen), intravenous, non-lyophilized, 500 mg.
J1554	Injection, immune globulin (asceniv), 500 mg.
J1556	Injection, immune globulin (bivigam), 500 mg.
J1557	Injection, immune globulin (gammaplex), intravenous, non-lyophilized, 500 mg.
J1561	Injection, immune globulin (gamunex-c/gammaked), non-lyophilized, 500 mg.
J1566	Injection, immune globulin, intravenous, lyophilized, not otherwise specified, 500 mg.
J1568	Injection, immune globulin (octagam), intravenous, non-lyophilized, 500 mg.
J1569	Injection, immune globulin (gammagard liquid), non-lyophilized, 500 mg.
J1572	Injection, immune globulin (flebogamma/flebogamma dif), intravenous, non-lyophilized, 500 mg.
J1576	Injection, immune globulin (panzyga), intravenous, non-lyophilized, 500 mg.

1–10 of 11

1/2

inv-06: CIDP electrodiagnostic thresholds

Motor distal latency≥ 50% prolongation above the upper limit of normal (ULN) in two nerves

Motor conduction velocity≥ 30% reduction below the lower limit of normal (LLN) in two nerves

F‑wave latency≥ 20% prolongation above ULN in two nerves, or >50% if distal negative peak CMAP amplitude is <80% of the LLN

Absence of F‑wavesAbsence of F‑waves in two nerves when those nerves have distal negative peak CMAP amplitudes ≥ 20% of the LLN, plus at least one other demyelinating parameter in another nerve

CMAP amplitude / partial motor conduction block≥ 50% amplitude reduction of the proximal negative peak CMAP relative to distal (partial motor conduction block) in two nerves, or in one nerve plus at least one other demyelinating parameter in another nerve

Temporal dispersion>30% increase in duration between proximal and distal negative peak CMAP in at least two nerves

Distal CMAP duration increase (specific nerves)Increase in distal CMAP duration in at least one nerve meeting thresholds: median ≥ 6.6 ms; ulnar ≥ 6.7 ms; peroneal ≥ 7.6 ms; tibial ≥ 8.8 ms (plus at least one other demyelinating parameter in another nerve)

Prescriber and Prior Authorization Requirements

Denial Risk

Insufficient diagnosis/consultation

Prior authorization is required with a documented diagnosis and when a specialist prescriber or consultation is specified in the coverage criteria. Absence of the required diagnosis or documented specialist consultation may result in denial of the request. Provide the specialist type listed in the indication (e.g., neurologist, hematologist, infectious disease specialist, allergist/immunologist, neonatologist) on the prior authorization.

Prior authorization must include the specific diagnosis from the coverage criteria.
List the specialist prescriber or attach documentation of consultation when the indication requires one.
Missing or unclear diagnosis or lack of required specialist consultation may lead to denial.

Documentation Required

Documentation required for 'Any other indication'

For any indication not explicitly listed in the coverage criteria, the request must include a diagnosis and supporting clinical documentation. Acceptable documentation includes chart notes and documentation of prior agents tried for the condition and why they were ineffective or inappropriate.

Include diagnosis and clinical justification in chart notes.
Document prior therapies tried and reasons for failure or contraindication.
Provide measurable clinical evidence where possible (e.g., lab results, imaging, symptom severity).

Prior Authorization

Required prior trials or refractory disease

Some indications require documentation of prior trials or demonstration of refractory disease before approval. Provide dates, agents, doses, duration, and reason for discontinuation or failure for prior therapies as specified by indication.

Examples of required prior trials or refractory documentation: ITP — trial of corticosteroids ineffective, not tolerated, or contraindicated; Dermatomyositis — refractory to at least one prior systemic therapy; Kawasaki disease — IVIG within 10 days of onset (timing requirement); Refractory myasthenia gravis — adequate trial (≥1 year) of glucocorticoids with azathioprine or mycophenolate (and other specified trials) was ineffective, contraindicated, or not tolerated; Stiff person syndrome — trials of benzodiazepine and baclofen products documented as ineffective/intolerant/contraindicated; Lambert-Eaton and related neuromuscular disorders — documentation of prior therapies or refractory status where specified.

Key Diagnostic Definitions

inv-12: CIDP diagnostic electrodiagnostic criteria

Prolonged motor distal latency≥ 50% prolongation above ULN in two nerves

Reduced motor conduction velocity≥ 30% reduction below LLN in two nerves

Prolonged F‑wave latency≥ 20% prolongation above ULN in two nerves, or >50% if distal CMAP amplitude <80% of LLN

Absence of F‑wavesAbsence in two nerves when distal negative peak CMAP ≥ 20% of LLN, plus at least one other demyelinating parameter in another nerve

Partial motor conduction block (CMAP)≥ 50% amplitude reduction of proximal vs distal negative peak CMAP in two nerves, or one nerve plus another demyelinating parameter in another nerve

Abnormal temporal dispersion>30% duration increase between proximal and distal negative peak CMAP in at least two nerves

Distal CMAP duration criteriaDistal CMAP duration increase in at least one nerve (median ≥6.6 ms; ulnar ≥6.7 ms; peroneal ≥7.6 ms; tibial ≥8.8 ms) plus ≥1 other demyelinating parameter in another nerve

Background

Intravenous immune globulin (IVIG) is used across specialties — including immunology, hematology, neurology, dermatology, infectious disease, and neonatology — to provide passive immunity or immunomodulation for a range of immunodeficiency, hematologic, neurologic, dermatologic, infectious, and pediatric inflammatory conditions. Many neurologic indications require specialist evaluation and objective testing or demonstration of benefit. Dosing, quantity limits, and authorization durations vary by indication and are specified elsewhere in this policy.